Callan Family Office LLC Invests $1.51 Million in AstraZeneca PLC (NASDAQ:AZN)

Callan Family Office LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 22,970 shares of the company's stock, valued at approximately $1,505,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Nordea Investment Management AB bought a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $754,000. Diversify Wealth Management LLC lifted its position in shares of AstraZeneca by 3.6% during the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company's stock valued at $295,000 after acquiring an additional 153 shares during the period. Ameritas Advisory Services LLC grew its holdings in shares of AstraZeneca by 25.9% during the 4th quarter. Ameritas Advisory Services LLC now owns 9,487 shares of the company's stock worth $622,000 after purchasing an additional 1,949 shares in the last quarter. Oak Ridge Investments LLC increased its position in shares of AstraZeneca by 5.4% in the fourth quarter. Oak Ridge Investments LLC now owns 143,973 shares of the company's stock worth $9,433,000 after purchasing an additional 7,341 shares during the period. Finally, Asio Capital LLC raised its stake in AstraZeneca by 11.6% in the fourth quarter. Asio Capital LLC now owns 53,541 shares of the company's stock valued at $3,508,000 after purchasing an additional 5,569 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.

AstraZeneca Price Performance

NASDAQ:AZN traded up $0.03 on Friday, hitting $77.50. The company had a trading volume of 7,022,104 shares, compared to its average volume of 5,679,263. AstraZeneca PLC has a 52 week low of $62.75 and a 52 week high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $240.34 billion, a price-to-earnings ratio of 34.29, a PEG ratio of 1.42 and a beta of 0.41. The firm has a 50 day moving average of $70.83 and a two-hundred day moving average of $72.74.

Remove Ads

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. On average, research analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Monday, March 24th. Stockholders of record on Friday, February 21st will be paid a dividend of $1.03 per share. This represents a dividend yield of 2%. This is a positive change from AstraZeneca's previous semi-annual dividend of $0.49. The ex-dividend date is Friday, February 21st. AstraZeneca's dividend payout ratio (DPR) is presently 91.15%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. UBS Group upgraded shares of AstraZeneca from a "neutral" rating to a "buy" rating in a research note on Thursday, February 13th. Morgan Stanley assumed coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They set an "overweight" rating on the stock. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.